• <rp id="rhqkq"><nav id="rhqkq"></nav></rp>
      <rt id="rhqkq"><optgroup id="rhqkq"><strike id="rhqkq"></strike></optgroup></rt>
      <rt id="rhqkq"><meter id="rhqkq"></meter></rt>
    1. <source id="rhqkq"><nav id="rhqkq"><strike id="rhqkq"></strike></nav></source>
      <rt id="rhqkq"><optgroup id="rhqkq"></optgroup></rt>
    2. <video id="rhqkq"><menuitem id="rhqkq"><em id="rhqkq"></em></menuitem></video>
    3. <rt id="rhqkq"><nav id="rhqkq"><button id="rhqkq"></button></nav></rt>

        ×

        Do you want to link to this External Site and leave Amgen.com?

        YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

        ×

        Do you want to link to this External Site and leave Amgen.com?

        YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

        ×

        Do you want to link to this External Site and leave Amgen.com?

        YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

        ×

        Do you want to link to this External Site and leave Amgen.com?

        YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

        ×

         

        Media

        Amgen Perspectives

        Read our submitted letters to editors and responses to Amgen news.

        Statements and Responses

        July 11, 2019
        Amgen Comments on PCSK9 Patent Litigation in Germany

        June 17, 2019
        Amgen Comments for ICER’s 2020 Value Assessment Framework

        June 14, 2019
        Helping Patients Understand the Price of Their Medicines

        May 2, 2019
        Amgen Reaches Settlement With Coherus in Trade Secrets Case Regarding Pegfilgrastim

        April 25, 2019
        Amgen Reaches Settlement Agreement To Resolve Allegations Related To Patient Assistance Programs

        February 21, 2019
        Amgen’s Comments on ICER’s Value-Based Price Of A Cure Collaborative: Methodological Considerations

        February 13, 2019
        Amgen’s Comments on ICER’s Price Increase Draft Protocol

        November 14, 2018
        Amgen Response in Support of the 2018 AHA/ACC Cholesterol Clinical Practice Guidelines

        July 27, 2018
        Amgen Statement on Pricing

        May 31, 2018
        Amgen Statement on Complete Response Letter from the U.S. FDA for ABP 980, a Biosimilar Candidate to Herceptin® (Trastuzumab)

        May 8, 2018
        Amgen Response to ICER’s Draft Evidence Report and Voting Questions on CGRP Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine

        March 7, 2018
        Amgen’s Final Summary Comments on ICER’s CAR-T Assessment

        January 19, 2017
        Amgen Response to ICER’s Draft Evidence Report and Voting Questions on CAR-T Therapy for B-Cell Cancers

        December 21, 2017
        Amgen’s Response to ICER’s Draft Scoping Document on Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value (Condition Update)

        December 20, 2017
        Amgen Response to ICER’s Draft Scoping Document on CGRP Preventive Therapy for Migraine

        November 30, 2017
        Amgen’s Statement on Cost Effectiveness of KYPROLIS® (carfilzomib) Compared to Velcade® (bortezomib) in Relapsed or Refractory Multiple Myeloma, Published in Expert Review of Hematology

        October 26, 2017
        Amgen Statement on the Economic Benefit of XGEVA® (denosumab) Versus Zoledronic Acid in the Prevention of Bone Complications in Multiple Myeloma

        October 25, 2017
        Amgen Provides Update on Status of Puerto Rico Operations

        October 6, 2017
        Amgen Provides Update on Status of Puerto Rico Operations

        October 5, 2017
        Amgen Statement on Appeals Court Decision on PCSK9 Antibody Patents

        September 25, 2017
        Amgen Response to ICER’s Proposed Adaptation of the ICER Value Framework for the Assessment of Treatments for Ultra-Rare Conditions

        August 31, 2017
        Amgen Response to ICER’s Draft Scoping Document on CAR-T Therapy for B-Cell Cancers

        June 30, 2017
        Amgen’s Position on Orphan Drugs and ICER’s Orphan Drug Assessment

        June 2, 2017
        Amgen’s Response to the Institute for Clinical and Economic Review (ICER) Draft Report on Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value

        May 5, 2017
        Amgen Response to ICER's Updated Value Assessment Framework - Recommendations for Value Assessment of PCSK9 Inhibitors

        Apr. 27, 2017
        Amgen Statement and Response to ICER Revised Value Framework Proposal and Osteoporosis Revised Scoping Document

        Apr. 23, 2017
        Amgen Response to Washington State Health Technology Assessment (HTA) Program's Draft Evidence Report on the Treatment of Chronic Migraines and Chronic Tension-type Headache

        Apr. 3, 2017
        Amgen’s Response to ICER’s Call for Comments on its “Updated” Value Framework - Executive Summary

        Feb. 16, 2017
        Amgen Statement and Response to ICER Rheumatoid Arthritis Draft Evidence Report

        Dec. 28, 2016
        Amgen Introduces New Value-Based Pharmacy Benefits Insurance Provision for U.S. Staff Members

        Oct. 20, 2016
        Amgen Response to ICER Plaque Psoriasis Draft Evidence Report

        Sep. 12, 2016
        Amgen Response to ICER’s Call for Comments on its Value Assessment Framework

        Sep. 9, 2016
        Amgen Statement on the Clinical and Economic Value of BLINCYTO® (Blinatumomab) in Treating Adults With Relapsed or Refractory Philadelphia Chromosome Negative B-Cell Precursor Acute Lymphoblastic Leukemia

        男人天堂7758